Anna K Dahlman (Former)
1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
AUTOMATED IMAGE ANALYSIS CONFIRMS THE PREDICTIVE SIGNIFICANCE OF MSMB IN PROSTATE CANCER
(
- Contribution to journal › Published meeting abstract
-
Mark
Translational perspectives on MSMB and CRISP3 expression and regulation in prostate cancer
(
- Thesis › Doctoral thesis (compilation)
-
Mark
CRISP-3 AND B-MSP ON PROSTATE CANCER NEEDLE-BIOPSIES DO NOT HAVE PREDICTIVE VALUE FOR SUBSEQUENT PROSTATECTOMY OUTCOME
2011) 26th Annual Congress of the European Association of Urology In European Urology Supplements 10(2). p.237-238(
- Contribution to journal › Published meeting abstract
-
Mark
Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
(
- Contribution to journal › Article
-
Mark
LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer
(
- Contribution to journal › Article
-
Mark
Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells.
(
- Contribution to journal › Article
-
Mark
Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis.
2011) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 24. p.708-719(
- Contribution to journal › Article
- 2010
-
Mark
Validation study of the prognostic significance of beta-microseminoprotein and cysteine-rich secretory protein-3 after radical prostatectomy using automated image analysis
2010) 21st Meeting of the European-Association-for-Cancer-Research In EJC Supplements 8(5). p.136-136(
- Contribution to journal › Published meeting abstract
-
Mark
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
(
- Contribution to journal › Article
- 2008
-
Mark
Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
(
- Contribution to journal › Article